ADAG

Adagene Inc. operates as a clinical-stage biopharmaceutical company focused on discovering and developing novel antibody-based cancer immunotherapies. Headquartered in Suzhou, China, with additional operations in San Diego, California, the company utilizes its proprietary SAFEbody and NEObody technology platforms to engineer precision antibodies designed to overcome limitations of traditional therapies. Adagene's pipeline includes multiple product candidates targeting various solid tumors, with lead programs ADG126 (CTLA-4 antibody) and ADG116 (CD137 agonist antibody) advancing through clinical trials. The company also develops bispecific antibodies through its SAFEbody platform, which aims to improve safety profiles while maintaining therapeutic efficacy. Adagene maintains strategic collaborations with major pharmaceutical companies, including a partnership with Sanofi established in 2020 focused on developing antibody therapies for cancer treatment. The company completed its initial public offering on Nasdaq in February 2021. Adagene's research efforts concentrate on immuno-oncology targets, with programs addressing checkpoint inhibitors, costimulatory receptors, and tumor microenvironment modulation. The company employs approximately 200 personnel across its facilities and maintains both discovery and development capabilities spanning early research through clinical development stages.